OncoMatch

OncoMatch/Clinical Trials/NCT07475403

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Is NCT07475403 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Systemic immunotherapy for bladder cancer.

Phase 2RecruitingTianjin Medical University Second HospitalNCT07475403Data as of May 2026

Treatment: Systemic immunotherapyThis study aims to evaluate whether urinary tumor DNA (utDNA) can guide treatment duration in patients with unresectable very-high-risk non-muscle-invasive bladder cancer (VHR NMIBC) who achieve complete clinical response after systemic immunotherapy. Participants will receive systemic immunotherapy followed by response assessment using pathology, cystoscopy, urine cytology, and utDNA testing. Patients who achieve complete clinical response will receive a short additional course of immunotherapy before stopping treatment according to the study protocol. The study hypothesizes that a shortened duration of systemic immunotherapy guided by utDNA monitoring may maintain favorable oncologic outcomes in this population.

Check if I qualify

Extracted eligibility criteria

Cancer type

Urothelial Carcinoma

Disease stage

Required: Stage NON-MUSCLE-INVASIVE, VERY-HIGH-RISK (VHR) PER EAU 2025 GUIDELINE (EAU 2025 guideline)

Excluded: Stage ≥T2

non-muscle-invasive urothelial carcinoma of the bladder classified as very-high-risk (VHR) according to EAU 2025 guideline criteria

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: immune checkpoint inhibitor

Prior treatment with immune

Lab requirements

Blood counts

absolute neutrophil count ≥1.5 × 10⁹/l, platelet count ≥100 × 10⁹/l, hemoglobin ≥9 g/dl

Kidney function

serum creatinine ≤1.5 × uln or creatinine clearance ≥60 ml/min

Liver function

total bilirubin ≤1.5 × uln, ast ≤2.5 × uln, alt ≤2.5 × uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify